Oncolytics Biotech, Inc. Common Shares - ONCY STOCK NEWS

Oncolytics Biotech has announced positive results from the phase 1b portion of its GOBLET study for pancreatic cancer, showing partial responses in all patients (n=3). The study evaluated pelareorep combined with chemotherapy and an anti-PD-L1 checkpoint inhibitor, meeting the criteria for expansion to additional patients. An independent review reported no toxicity concerns, suggesting potential for improved treatment approaches in pancreatic cancer, which has limited standard treatment efficacy. The findings will be featured at the ESMO World Congress on Gastrointestinal Cancer.

Oncolytics Biotech Inc. (NASDAQ: ONCY) held its Annual General Meeting (AGM) on June 16, 2022, with a shareholder turnout of 40.43%. James T. Parsons was elected to the Board of Directors, replacing Leonard Kruimer who did not seek re-election. Mr. Parsons, a seasoned executive with over 20 years in the life sciences sector, previously served as CFO at Trillium Therapeutics before its acquisition by Pfizer for $2.2 billion. The meeting also approved all resolutions, including the number of directors and the appointment of auditors for the upcoming year.

Oncolytics Biotech (NASDAQ: ONCY) has announced that Dr. Matt Coffey, President and CEO, will participate in a fireside chat at the 2022 RBC Capital Markets Global Healthcare Conference on May 18, 2022, at 11:00 a.m. ET. The conference will be held at the InterContinental New York Barclay. A live webcast of the presentation will be available on the company’s Investor Relations page and archived until August 15, 2022. Oncolytics is developing pelareorep, an immunotherapeutic agent aimed at treating various cancers.

Oncolytics Biotech announced key operational highlights and financial results for Q1 2022, with a cash position of $39.5 million expected to fund upcoming milestones. The company reported positive clinical data for its lead drug, pelareorep, showing improved patient outcomes in HR+/HER2- breast cancer and successful combinations with CAR T therapies in preclinical studies. Operating expenses decreased from $3.1 million to $2.6 million year-over-year, though net loss increased to $6.8 million. Upcoming milestones include data from the BRACELET-1 study in Q4 2022.

On May 4, 2022, Oncolytics Biotech announced favorable results from its AWARE-1 study on pelareorep for HR+/HER2- breast cancer. The treatment demonstrated a 100% favorable Risk of Recurrence Score (ROR-S) in evaluable patients, up from 55% at baseline. Increases in tumor cell death markers and T cell activation were also noted. The study's findings support pelareorep's potential to enhance clinical outcomes by transforming tumors into less aggressive types. Future clinical trials, including BRACELET-1, aim to further evaluate its effectiveness.

Oncolytics Biotech Inc. (NASDAQ: ONCY) has announced that its abstract, detailing results from the AWARE-1 study, has been accepted for presentation at the European Society for Medical Oncology Breast Cancer Meeting from May 3-5, 2022, in Berlin. The study evaluated the oncolytic virus pelareorep combined with letrozole and atezolizumab in early-stage breast cancer patients. Results suggest pelareorep may enhance immune responses and improve treatment outcomes. The presentation is scheduled for May 4, 2022, at 12:15 p.m. CET, focusing on innovative cancer therapies.

Oncolytics Biotech Inc. (NASDAQ: ONCY) will host a conference call and webcast on May 5, 2022, at 5:00 p.m. ET to discuss its first-quarter financial results and corporate update. Pelareorep, an immunotherapeutic agent being developed by Oncolytics, is under evaluation for its efficacy in treating various cancers. The company is moving towards a registration study for metastatic breast cancer and is conducting clinical trials in combination with other therapies. Investors can access the webcast via the Investor Relations page on Oncolytics' website.

Oncolytics Biotech Inc. (NASDAQ: ONCY) announced that CEO Dr. Matt Coffey will present a corporate overview at the Bloom Burton & Co. Healthcare Investor Conference on May 3, 2022, at 11:00 a.m. ET in Toronto. The conference will feature updates from Canadian healthcare companies and offer one-on-one investor meetings. A live webcast of the presentation will be available on Oncolytics' Investor Relations page and archived for three months. The company focuses on developing the immunotherapeutic agent pelareorep to enhance anti-cancer immune responses.

Oncolytics Biotech Inc. (NASDAQ: ONCY) announced the publication of preclinical data showing that pelareorep significantly enhances the efficacy of CAR T cell therapy in treating solid tumors. The study, published in Science Translational Medicine, demonstrates that pelareorep-loaded CAR T cells exhibit improved persistence and anti-cancer activity in various murine solid tumor models. This combination may address key challenges faced by CAR T therapies in solid tumors, potentially increasing treatment options for patients. The findings suggest a promising avenue for clinical application.